Podcast: Prof Klaus Schmierer on vaccine readiness for people with MS on cladribine

Sponsored by Merck Healthcare Pty Ltd

Data suggests that people with MS treated with cladribine are able to mount a protective immune response after influenza and varicella zoster vaccination regardless of the timing of the vaccine relative to the cladribine dose and independent of lymphocyte counts. Real-world data has also shown that cladribine does not impair the humoral response to COVID-19 ...

Already a member?

Login to keep reading.

© 2021 the limbic